News on emerging technologies in healthcare
Welcome to the NIHR Horizon Scanning Centre website. The NIHR HSC aims to supply timely information to key health policy and decision-makers within the NHS about emerging health technologies that may have a significant impact on patients or the provision of health services in the near future.
The scope of our activity includes pharmaceuticals, medical devices and equipment, diagnostic tests and procedures, therapeutic interventions, rehabilitation and therapy, and public health activities.
Top 20 reports
downloaded:
1. Pirfenidone for idiopathic pulmonary fibrosis - Apr 2011
2. Serelaxin for acute decompensated heart failure – in addition to IV diuretics - Aug 2012
3. Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics - Jun 2012
4. Sofosbuvir for chronic hepatitis C infection with compensated liver disease - Oct 2012
5. Agomelatine (Valdoxan) for generalised anxiety disorder – first or second line - Jul 2011
6. Secukinumab for plaque psoriasis - May 2012
7. Silodosin (Rapaflo) for benign prostatic hyperplasia - Apr 2011
8. Alipogene tiparvovec (AMT-011, Glybera) for lipoprotein lipase deficiency - Apr 2011
9. Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes - Jul 2011
10. Golimumab (Simponi) for ulcerative colitis – second line - Oct 2011
11. Regorafenib for metastatic colorectal cancer - third or fourth line - Oct 2011
12. Umeclidinium and vilanterol for chronic obstructive pulmonary disease - Mar 2012
13. LINX™ Reflux Management System for gastro-oesophageal reflux disease (GORD) - May 2011
14. Canagliflozin for type 2 diabetes mellitus - Jul 2011
15. Enhanced liver fibrosis (ELF) test for liver fibrosis - diagnosis - Apr 2011
16. Empagliflozin for type 2 diabetes mellitus - May 2012
17. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain - Aug 2012
18. Argus II™ Retinal Prosthesis System for peripheral retinal degeneration - Jul 2011
19. Eculizumab (Soliris) for atypical haemolytic uraemic syndrome – first line - Oct 2011
20. Tadalafil (Cialis) for benign prostatic hyperplasia - Apr 2011
